ID: ALA505727

Max Phase: Preclinical

Molecular Formula: C34H32N4O4

Molecular Weight: 560.65

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1cccc(-n2cc(C(=O)N3CCN(c4cc(C(=O)O)c5ccccc5c4)CC3)nc2-c2ccc(C)cc2)c1

Standard InChI:  InChI=1S/C34H32N4O4/c1-3-42-28-9-6-8-26(20-28)38-22-31(35-32(38)24-13-11-23(2)12-14-24)33(39)37-17-15-36(16-18-37)27-19-25-7-4-5-10-29(25)30(21-27)34(40)41/h4-14,19-22H,3,15-18H2,1-2H3,(H,40,41)

Standard InChI Key:  HMGSYODAZJHCRL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 560.65

Molecular Weight (Monoisotopic): 560.2424

AlogP: 6.06

#Rotatable Bonds: 7

Polar Surface Area: 87.90

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.34

CX Basic pKa: 2.78

CX LogP: 6.33

CX LogD: 3.59

Aromatic Rings: 5

Heavy Atoms: 42

QED Weighted: 0.26

Np Likeness Score: -1.29

References

1. Berger R, Zhu C, Hansen AR, Harper B, Chen Z, Holt TG, Hubert J, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, Wolff M, Macneil DJ, Weber AE, Edmondson SD..  (2008)  2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.,  18  (17): [PMID:18684621] [10.1016/j.bmcl.2008.07.083]

2. Zhu C, Hansen AR, Bateman T, Chen Z, Holt TG, Hubert JA, Karanam BV, Lee SJ, Pan J, Qian S, Reddy VB, Reitman ML, Strack AM, Tong V, Weingarth DT, Wolff MS, MacNeil DJ, Weber AE, Duffy JL, Edmondson SD..  (2008)  Discovery of imidazole carboxamides as potent and selective CCK1R agonists.,  18  (15): [PMID:18614364] [10.1016/j.bmcl.2008.06.057]

Source

Source(1):

• Scientific Literature